Pomerantz Law Firm Investigates Potential Investor Claims Against Theravance Biopharma, Inc.

Investigative Alert: Pomerantz Law Firm's Inquiry into Theravance Biopharma, Inc.

In a significant development for investors of Theravance Biopharma, Inc. (NASDAQ: TBPH), the Pomerantz Law Firm has initiated an investigation into potential securities fraud and unlawful business practices perpetrated by the company and its executives. This inquiry comes on the heels of alarming disclosures that have raised serious concerns about the company's integrity and future prospects.

On March 3, 2026, Theravance made headlines when it released disappointing topline results from its Phase 3 CYPRESS study. This pivotal study aimed to evaluate the safety and efficacy of ampreloxetine in treating neurogenic orthostatic hypotension due to multiple system atrophy, a rare but debilitating condition. Unfortunately, the study did not meet its primary endpoint, resulting in the decision to wind down the ampreloxetine program altogether. The fallout was immediate; Theravance's stock price plummeted by $4.99, translating to a staggering 26.33% drop, closing at $13.96.

This drastic decline has prompted Pomerantz LLP to reach out to investors who might have been adversely affected by these events. The firm is urging these investors to contact Danielle Peyton at [email protected] or via phone at 646-581-9980, extension 7980, to discuss potential claims against Theravance.

Pomerantz Law Firm is widely regarded as a leading authority in corporate litigation, particularly in the realms of securities and antitrust class actions. Founded by the trailblazer Abraham L. Pomerantz, who was known as the father of class action law, the firm has established a strong legacy over its 85+ year history. The firm has successfully secured multimillion-dollar settlements for class members impacted by corporate fraud, underscoring their commitment to fighting for victims of securities misconduct.

The investigation spearheaded by Pomerantz focuses on whether Theravance and its officers violated securities laws through deceptive practices. Given the recent developments regarding the CYPRESS study and the subsequent plunge in stock value, investors are being called upon to ensure their voices are heard and accountabilities are met.

It is crucial for investors to keep abreast of these unfolding developments regarding Theravance Biopharma, Inc., as the ramifications of the company's decisions may continue to impact stock performance. The collective action of affected investors could lead to significant legal outcomes and potentially, substantial recoveries for those who suffered losses due to perceived malpractice.

For more information and assistance regarding the ongoing investigation or to participate in the potential class action, interested investors can visit Pomerantz Law Firm's official website or contact the provided number.

As the situation continues to evolve, stakeholders should remain vigilant, as the implications of these findings could extend beyond mere financial returns, touching on broader issues of corporate governance and ethical standards in the biotechnology sector.